Protocatechualdehyde

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Natural Science Foundation of China and 1 more

Model organisms1

Outcomes

Lipofuscin

downin worms1

1 study

Protocatechualdehyde decreases lipofuscin in worms.
“reducing lipofuscin accumulation.”
Model organismsin an AD model2 mM
3,4-Dihydroxybenzaldehyde Exerts Anti-Alzheimer's Effects by Inhibiting Aβ Protofibril Assembly and Activating Antioxidant Defense Mechanisms
International journal of molecular sciences6 Feb 2026

Latest

1 in 12 months

International Journal of Molecular Sciences13 Feb

3,4-Dihydroxybenzaldehyde Exerts Anti-Alzheimer's Effects by Inhibiting Aβ Protofibril Assembly and Activating Antioxidant Defense Mechanisms

Experiments in wormsAlzheimer's disease

Paper

Protocatechualdehyde

Outcomes

Latest

3,4-Dihydroxybenzaldehyde Exerts Anti-Alzheimer's Effects by Inhibiting Aβ Protofibril Assembly and Activating Antioxidant Defense Mechanisms

Related